A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Summary

This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.

Timeline

Start

2021-11-29

Primary completion

2022-09-29

Completion

2022-09-29

Outcome

Met primary endpoint

release “目前，依若奇治疗中重度银屑病的III期关键注册性临床已达到主要研究终点.” akesobio.com ↗

Drugs

Indications